Research and insights
Coverage audits, landscape analyses, and method notes from the TrialForge team. How the data is built, and what it reveals.
3 insights
ResearchSeptember 2026
TrialForge tracks IQVIA trends within 2 percent, and adds the 40 to 50 percent of China's industry trials that ClinicalTrials.gov does not hold
TrialForge follows IQVIA's global trial start trends and adds the China trials ClinicalTrials.gov does not hold.
Read the note →Research
We added China's drug trial registry. Here's what ClinicalTrials.gov alone misses
Three of every four CDE trials is not on ClinicalTrials.gov, a 63 percent bigger picture of China plus thousands of novel CDE-only drug assets.
Read the note →Coverage audit
Our coverage of cardiorenalmetabolic assets
The audit, in full: 100 percent of clinical-stage cardiorenalmetabolic assets with a ClinicalTrials.gov trial, held in TrialForge.
Read the note →